# Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
Canonical URL: https://biopharmsignal.com/news/LYEL/lyell-announces-two-oral-presentations-from-the-phase-1-2-clinical-trial-of-ronde-cel-for-the-treatment-of-aggressive-large-b-cell-lymphoma-at-the-67th-ash-annual-meeting-and-exposition
Ticker: LYEL
Company: Lyell Immunopharma
Source: Lyell Immunopharma
Published: 2025-11-03 14:00 EST
Original Source URL: https://ir.lyell.com
## Summary

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that two abstracts highlighting new clinical and translational

## Article Body
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that two abstracts highlighting new clinical and translational
## Recent Company News
- 2026-06-01 12:00 EST — [Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-participation-in-goldman-sachs-47th-annual-global-healthcare-conference-2026) — Source: Lyell Immunopharma
- 2026-05-12 12:00 EST — [Lyell Immunopharma Announces Participation in May Investor Conferences](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-participation-in-may-investor-conferences) — Source: Lyell Immunopharma
- 2026-05-06 20:05 EST — [Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-first-quarter-2026) — Source: Lyell Immunopharma
- 2026-04-07 12:00 EST — [Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-participation-in-25th-annual-needham-virtual-healthcare-conference) — Source: Lyell Immunopharma
- 2026-03-12 20:05 EST — [Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-reports-q4-and-full-year-2025-business-and-financial-results) — Source: Lyell Immunopharma
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)